Cargando…
The Promise of Novel Molecular Markers in Bladder Cancer
Bladder cancer is the fourth most common malignancy in the US and is associated with the highest cost per patient. A high likelihood of recurrence, mandating stringent surveillance protocols, has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burde...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284796/ https://www.ncbi.nlm.nih.gov/pubmed/25535079 http://dx.doi.org/10.3390/ijms151223897 |
_version_ | 1782351466684481536 |
---|---|
author | Miremami, Jahan Kyprianou, Natasha |
author_facet | Miremami, Jahan Kyprianou, Natasha |
author_sort | Miremami, Jahan |
collection | PubMed |
description | Bladder cancer is the fourth most common malignancy in the US and is associated with the highest cost per patient. A high likelihood of recurrence, mandating stringent surveillance protocols, has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burden this disease places on patients and the healthcare system. To date, routine use of markers is not recommended for screening or diagnosis. Interests include the development of a single urinary marker that can be used in place of or as an adjunct to current screening and surveillance techniques, as well identifying a molecular signature for an individual’s disease that can help predict progression, prognosis, and potential therapeutic response. Markers have shown potential value in improving diagnostic accuracy when used as an adjunct to current modalities, risk-stratification of patients that could aid the clinician in determining aggressiveness of surveillance, and allowing for a decrease in invasive surveillance procedures. This review discusses the current understanding of emerging biomarkers, including miRNAs, gene signatures and detection of circulating tumor cells in the blood, and their potential clinical value in bladder cancer diagnosis, as prognostic indicators, and surveillance tools, as well as limitations to their incorporation into medical practice. |
format | Online Article Text |
id | pubmed-4284796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-42847962015-01-21 The Promise of Novel Molecular Markers in Bladder Cancer Miremami, Jahan Kyprianou, Natasha Int J Mol Sci Review Bladder cancer is the fourth most common malignancy in the US and is associated with the highest cost per patient. A high likelihood of recurrence, mandating stringent surveillance protocols, has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burden this disease places on patients and the healthcare system. To date, routine use of markers is not recommended for screening or diagnosis. Interests include the development of a single urinary marker that can be used in place of or as an adjunct to current screening and surveillance techniques, as well identifying a molecular signature for an individual’s disease that can help predict progression, prognosis, and potential therapeutic response. Markers have shown potential value in improving diagnostic accuracy when used as an adjunct to current modalities, risk-stratification of patients that could aid the clinician in determining aggressiveness of surveillance, and allowing for a decrease in invasive surveillance procedures. This review discusses the current understanding of emerging biomarkers, including miRNAs, gene signatures and detection of circulating tumor cells in the blood, and their potential clinical value in bladder cancer diagnosis, as prognostic indicators, and surveillance tools, as well as limitations to their incorporation into medical practice. MDPI 2014-12-22 /pmc/articles/PMC4284796/ /pubmed/25535079 http://dx.doi.org/10.3390/ijms151223897 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Miremami, Jahan Kyprianou, Natasha The Promise of Novel Molecular Markers in Bladder Cancer |
title | The Promise of Novel Molecular Markers in Bladder Cancer |
title_full | The Promise of Novel Molecular Markers in Bladder Cancer |
title_fullStr | The Promise of Novel Molecular Markers in Bladder Cancer |
title_full_unstemmed | The Promise of Novel Molecular Markers in Bladder Cancer |
title_short | The Promise of Novel Molecular Markers in Bladder Cancer |
title_sort | promise of novel molecular markers in bladder cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284796/ https://www.ncbi.nlm.nih.gov/pubmed/25535079 http://dx.doi.org/10.3390/ijms151223897 |
work_keys_str_mv | AT miremamijahan thepromiseofnovelmolecularmarkersinbladdercancer AT kyprianounatasha thepromiseofnovelmolecularmarkersinbladdercancer AT miremamijahan promiseofnovelmolecularmarkersinbladdercancer AT kyprianounatasha promiseofnovelmolecularmarkersinbladdercancer |